To find the optimal Primimg dose and side effects associated with Atracurium

Prospective comparative randomized controlled study to determine the optimal priming dose of atracurium

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012622

Enrollment

Registered

2018-03-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- All were good at the time of trial

Interventions

Intervention1: three groups group A ,B,C: Group A-0.05 mg of priming dose group B-0.025 mg of atracurium Group C- control Intervention2: Atracurium: Group A dose - 0.05 mg/kg through IV route and rema

Eligibility

Inclusion criteria

Inclusion criteria: ASA 1,2 Patients

Exclusion criteria

Exclusion criteria: pregnancy patients, ASA 3,4 Patients

Design outcomes

Primary

Measure	Time frame
Priming dose of atracuriumTimepoint: Priming dose of atracurium at the end of 3 minutes side effects were monitored and also PNS started to find out the time of onset of action	—

Secondary

Measure	Time frame
side effects with primingTimepoint: at the end of 3 minutes	—

Countries

India

Contacts

Public ContactDr Arun kumar H D

Kasturba Medical College Hospital,Manipal

kordcal85@gmail.com08202922110

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026